New research from the Abramson Cancer Center at the University of Pennsylvania, published in the May 2019 issue of the Journal of the National Comprehensive Cancer Network uses a large, real-world dataset to demonstrate there is a modest but consistent survival benefit associated with adding bevacizumab to carboplatin-pemetrexed when treating advanced non-squamous non-small cell lung cancer.
UPenn study shows adding bevacizumab improves OS in NSCLC
YOU MAY BE INTERESTED IN
President Joe Biden April 9 announced his FY2022 budgetary plans for ARPA-H—Advanced Research Projects Agency-Health—a federal entity designed to “deliver breakthroughs to find cures for cancer and other diseases.” In his initial White House budget proposal—dubbed skinny budget, or budget-lite—Biden is requesting $6.5 billion to fund ARPA-H. “The discretionary request calls for $6.5 billion to...
Today Dr. Roswell Park is remembered mostly as the founder of the world’s first cancer research institute, which still bears his name proudly to this day in Buffalo, NY, but his contributions to medicine extend much further.